Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 261-263

  Jendle, J ^a,b   Ridderstrale M ^c   Torfvitt, O ^c   Ericsson, A ^d   Larsen, S ^d  

^a Karlstad Hospital   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Novo Nordisk Scandinavia   (Sweden)

Author keywords

Basal insulin; Discrete choice experiments; Health economics; Hypoglycemia; Insulin detemir; NPH insulin; Type 2 diabetes; Willingness to pay

Indexed keywords

INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

ARTICLE; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; ECONOMIC EVALUATION; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MEDICAL FEE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; SIDE EFFECT; SWEDEN; TREATMENT OUTCOME; WEIGHT GAIN; WILLINGNESS TO PAY;

DIABETES MELLITUS, TYPE 2; FINANCING, PERSONAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PREFERENCE; PROXY; SWEDEN;

EID: 84858121088     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.644408     Document Type: Article

References (10)

1. Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 2007;99:357-60, 363-7
2. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-9
3. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372-8
4. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74 (Pubitemid 44125921)
5. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81 (Pubitemid 44856694)
6. Nationella riktlinjer fö r diabetesva° rden 2010-stöd fö r styrning och ledning. [National diabetes guidelines-support for governance and management.] Stockholm, Sweden; 2010
7. Jendle J, Torffvit O, Ridderstrale M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917-23
8. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(1 Suppl):S11-61
9. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-totarget trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
10. Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care 2006;29:1249-55 (Pubitemid 44125918)